GSE111247 temozolomide LN-308 2 v 4 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE111247_temozolomide_LN-308_2_v_4_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE111247_temozolomide_LN-308_2_v_4_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE111247_temozolomide_LN-308_2_v_4_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE111247_temozolomide_LN-308_2_v_4_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

OIP5 antisense RNA 1

Gene

cutA divalent cation tolerance like, pseudogene

Gene

long intergenic non-protein coding RNA 1278

Gene

CNN3 divergent transcript

Gene

MBNL1 antisense RNA 1

Gene

TNS2 antisense RNA 1

Gene

ZFAND2A divergent transcript

Gene

ZFHX4 antisense RNA 1

Gene

OTUD6B antisense RNA 1

Gene

CDKN2B and CDKN2A antisense cis and trans regulatory RNA 1

  • Gene

    OIP5 antisense RNA 1


  • Gene

    cutA divalent cation tolerance like, pseudogene


  • Gene

    long intergenic non-protein coding RNA 1278


  • Gene

    CNN3 divergent transcript


  • Gene

    MBNL1 antisense RNA 1


  • Gene

    TNS2 antisense RNA 1


  • Gene

    ZFAND2A divergent transcript


  • Gene

    ZFHX4 antisense RNA 1


  • Gene

    OTUD6B antisense RNA 1


  • Gene

    CDKN2B and CDKN2A antisense cis and trans regulatory RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.